Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension

OBJECTIVE: Endothelin (ET) receptor antagonists (ERAs) have considerable improvements in pulmonary arterial hypertension (PAH) patients’ symptoms. Macitentan, a novel ERA, has more significant positive effects like reduction of morbidity and mortality in PAH patients by 45% and decreases PAH hospita...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Family Med Prim Care
Main Authors: Nosrati, Marzieh, Shahmirzadi, Nikinaz Ashrafi, Afzali, Monireh, Zaboli, Pardis, Rouhani, Hasti, Hamedifar, Haleh, Hajimiri, Mirhamed
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer - Medknow 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7567197/
https://ncbi.nlm.nih.gov/pubmed/33102342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/jfmpc.jfmpc_1166_19
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados